November 18, 2024 at 12:30 pm US EST
This presentation will cover the progress made in the clinical management and treatment of individual patients with personalized antisense oligonucleotides, highlighting operational challenges, and providing high-level clinical observations.
Dr. Laurence Mignon is the executive director of clinical development at n-Lorem Foundation. Laurence has more than 20 years of experience as a seasoned academic researcher and clinical developer with a passion for rare diseases. Most recently, Laurence worked at Ionis Pharmaceuticals both in the Translational Medicine group and the Neurology Franchise Clinical Development group. In those roles, she implemented a novel genomic study to better understand genotype-phenotype associations and disease pathways, initiated the first clinical study in myotonic dystrophy type 1 and was a key member of the clinical team that brought SPINRAZA® (nusinersen), a disease-modifying therapy for patients with spinal muscular atrophy, to the market. Prior to Ionis, Laurence worked at Orexigen Therapeutics on the development of an obesity medication and at the Neuroscience Education Institute developing Continuing Medical Education material aimed at deconstructing the mechanism of action of psychiatric medications for psychiatrists, primary care physicians, and registered nurses. Laurence’s broad and diverse experience allows her to be strategically creative in her approach to deal with uncharted challenges. Laurence received her PhD in Pharmacology and Experimental Therapeutics from Loyola University Chicago and was a researcher for 6 years in the Department of Neurology at UCLA in the laboratory of Marie-Françoise Chesselet, studying properties of muscle-derived stem cells and the role of the serotonin pathway in Parkinson’s disease.
コメント